The prevalence of homologous recombination deficiency (HRD) in various solid tumors and the role of HRD as a single biomarker to immune checkpoint inhibitors
CONCLUSION: Herein, we reported the status of HRD using a cancer-panel for various solid tumor patients in routine clinical practice and demonstrated that HRD as a single biomarker was not sufficient to predict efficacy of ICIs in solid tumor patients.PMID:34510272 | DOI:10.1007/s00432-021-03781-6
Source: Clinical Colorectal Cancer - Category: Cancer & Oncology Authors: Hana Kim Soomin Ahn Hongsik Kim Jung Yong Hong Jeeyun Lee Se Hoon Park Joon Oh Park Young Suk Park Ho Yeong Lim Won Ki Kang Kyoung-Mee Kim Seung Tae Kim Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Colorectal Cancer | Gastroenterology | Hepatocellular Carcinoma | Immunotherapy | Liver Cancer | Melanoma | Pancreas | Pancreatic Cancer | Sarcomas | Skin Cancer | Statistics